readi turn anoth revolut
bergenbio report promis result broad phase ii programm
bemcentinib focuss acut myeloid leukaemia aml non-smal cell lung
cancer nsclc throughout notabl data studi
nsclc combin inhibitor pembrolizumab patient
neg tumour respond well therapi result thu far indic
import biomark identifi patient axl tumour
like benefit bemcentinib compani plan seri randomis
phase ii trial confirm find date due start
bergenbio also two product enter clinic develop
valu compani
share issu
triniti delta note cash posit includ capit rais adjust number
initi phase ii result support broad potenti bemcentinib promis efficaci
signal detect phase ii studi data show well
bemcentinib well-toler monotherapi combin includ
pembrolizumab docetaxel erlotinib parallel evalu biomark indic
express blood test activ could identifi patient like
respond bemcentinib form basi companion diagnost test
phase iib programm start qualiti phase ii proof-of-concept
data far led bergenbio plan randomis phase iib trial start
detail disclos yet believ
phase iib studi nsclc like combin
inhibitor pembrolizumab mds/aml use
valid potenti companion diagnost identifi current studi
move one three clinic programm bemcentinib advanc
select small molecul inhibitor clinic develop howev bergenbio
also biolog target pipelin anti-axl antibodi
antibodi drug conjug partner
recent enter phase test healthi volunt patient
current valuat fail reflect potenti target valu bergenbio
increas valuat
enter clinic increasingli recognis
import oncolog target given role mani aggress cancer
bemcentinib lead select small molecul inhibitor develop
believ data sever phase ii trial come year highlight
bemcentinib potenti act catalyst share
bergenbio clinical-stag
biopharmaceut compani base
bergen norway oxford uk
develop innov therapi
aggress cancer way
inhibit signal pathway
bemcentinib multipl phase ii
triniti pioneer inhibit
fund
clinic risk reduc
still major consider
bergenbio clinic stage biopharmaceut compani focuss exploit
knowledg signal pathway drug target found
prof jame loren univers bergen norway pioneer
work understand role biolog led compani
becom leader field first-in-class select inhibitor
bemcentinib collabor merck co bemcentinib
evalu broad proof concept phase ii programm singl agent
combin therapi compani also assess two approach
inhibit monoclon antibodi antibody-drug
april bergenbio list oslo exchang rais
gross rais april compani
employ peopl research facil bergen clinic
develop function oxford uk
bergenbio classic biotechnolog compani well suit valuat use
rnpv model ascrib risk-adjust valu bemcentinib
indic bergenbio current pursu conserv estim
potenti gener core valuat compani top
includ estim bemcentinib broader potenti immuno-
oncolog gener total valuat bergenbio use approach
core valuat bergenbio per share
total compani valuat per share
conserv place valu stage
core valuat bergenbio current share price total
compani valuat highlight sever catalyst
drive upsid next year data current clinic
trial throughout randomis phase ii studi due start
bergenbio cash posit rais
gross april allow
compani oper bergenbio regularli report
data broad phase ii programm possibl bemcentinib
partner interim would significantli extend cash runway
typic industri risk associ clinic trial regulatori hurdl financ
possibl partner discuss eventu price commercialis
appli promis data variou clinic trial reduc clinic trial risk
associ bemcentinib howev result date far limit
number patient still novel therapeut target success clinic
develop bemcentinib would clearli posit
bergenbio forefront excit attract area howev inevit
innov still carri higher risk key near-term sensit relat
result variou oncolog trial current underway whether bergenbio
opt out-licens bemcentinib stage expect seek partner
bergenbio readi anoth revolut
past year clinic data variou proof-of-concept phase ii trial
oncolog support broad potenti inhibitor bemcentinib
particularli case nsclc result far suggest bemcentinib
enhanc activ pembrolizumab immunotherapi erlotinib targeted-
therapi docetaxel chemotherapi similarli posit result
aml activ increas bergenbio plan next
stage clinic develop randomis phase ii trial due start
detail releas date compani also advanc antibodi
clinic partner start phase
studi valu bergenbio
bergenbio one first compani recognis potenti
target drug develop thank research prof jame loren
univers bergen norway receptor known involv
enabl tumour escap immun surveil develop resist
variou oncolog therapi also play role patholog
bergenbio leader field bemcentinib advanc select
oral inhibitor clinic develop well antibodi
antibody-drug conjug earli clinic develop
promis data proof-of-concept studi bemcentinib nsclc
aml confirm compound potenti variou set notabl
overal respons rate bemcentinib combin
pembrolizumab nsclc patient group expect
respond inhibitor importantli patient axl-
posit tumour respond best bemcentinib orr support
bemcentinib propos mode action similar result observ
aml/md bemcentinib monotherapi also encourag result
nsclc studi combin erlotinib docetaxel
bergenbio integr companion diagnost programm bemcentinib
phase ii studi top clear clinic regulatori benefit associ
abil identifi patient like respond treatment could
provid import competit advantag bergenbio identifi
biomark appear classifi patient like respond bemcentinib
treatment valid phase ii/iii studi
compani current plan randomis phase ii programm due
begin detail yet disclos expect centr
bemcentinib potenti nsclc aml/md also like
design trial could becom pivot studi support nda file
us europ therebi expedit rout market
bergenbio also recent start phase studi healthi volunt
antibodi view start proof-of-concept phase ii trial
compani yet disclos indic highlight
potenti oncolog variou fibrot indic bergenbio
third product clinic develop partner
therapeut recent initi phase studi variou solid tumour
recognis leader
promis field inhibit
encourag result seen
number clinic set
diagnost integr
signific phase ii studi set
progress clinic
lead field target
bergenbio built solid scientif foundat build pipelin target
potenti receptor oncolog target recognis
lead product bemcentinib advanc select oral inhibitor
develop promis result report proof-of-
concept phase ii exhibit asset recent enter clinic
ad antibodi antibody-drug-conjug clinic
pioneer promis
bergenbio note clinic trial collabor preferenti right investigator-initi trial iit /investigator-l studi il
attract oncolog target stem fact appear
play import role format aggress cancer includ
metastasi develop resist tumour cell immuno-
oncolog chemotherapeut targeted-therapeut agent bergenbio
conduct number proof-of-concept phase ii studi monotherapi
combin variou therapi focu nsclc mds/aml
plan randomis phase ii trial start
data trial date combin underli scienc
attract increas number investigator-l studi il initi
intern key-opinion-lead kol exhibit help
bergenbio gain better understand bemcentinib abil treat differ
tumour aspir establish cornerston therapi cancer
receptor member tyro mer receptor tyrosin kinas
famili close associ inflamm preval malign
particularli aggress tumour limit function normal
tissu inde phase studi bemcentinib healthi volunt conduct
bergenbio indic safe well-toler per day
dose per day use current phase ii clinic trial
close link aggress
fulli recruit orr
nsclc
fulli recruit deepen
respons respons
observ
expect
on-going efficaci endpoint
orr pt stage
met stage enrol
recruit pt total
efficaci endpoint met
pt -ve tumour
bergenbio clinicaltri gov note company-l studi black investigator-l studi blue aml acut myeloid leukaemia
cancer first patient
exhibit signal pathway activ signal
epitheli mesenchym
transit emt major factor
aggress tumour
receptor activ sole ligand turn lead
activ differ signal pathway depend cell type affect
notabl oncolog perspect signal result immuno-
suppress via signal promot cell surviv via mtor signal
epithelial-to-mesenchym transit via twist snail activ
net effect signal tumour
promot format drug resist via combin emt
process signal
lead format metastat cancer via emt process
make tumour cold less immunogen -via emt process
enabl tumour cell escap immuno-surveil three key
chang occur emt tumour cell exhibit firstli reduc
express mhci protein major histocompat class protein
protein present protein fragment cytotox t-cell secondli emt cell
form effect immunolog synaps cytotox t-cell
prevent destruct thirdli mesenchym tumour cell promot
immunosuppress tumour microenviron preclin studi
radiat sensit resist tumour cell line inhibit shown
increas infiltr cytotox t-cell
exhibit axl-driven epithelial-mesenchym transit tumour cell
emt process cell chang polaris epitheli cell tightli
join neighbour cell becom mesenchym cell amorph
shape like migrat emt express hundr gene chang
enabl acquisit new cellular characterist
top innat immun checkpoint immun respons
pathway activ macrophag dendrit cell
cytokin ifn- bind ifn receptor crucial stimul innat
respons infect prevent excess immun respons
also safeti switch trigger increas express result
activ gene regul pro-inflammatori cytokin
import action cytotox t-cell
consist effect signal tumour cell high express
receptor associ aggress cancer poor prognosi
patient exhibit receptor normal present low level adult
tissu upregul around half tumour variat
accord tumour type
interestingli receptor rare mutat unlik tumour-associ
tyrosin kinas receptor bergenbio identifi resist
mutat bemcentinib
mostli associ
exhibit prognosi breast lung aml patient high low level express
bemcentinib well toler
combin therapi
studi date
bemcentinib readi take next step
bemcentinib evalu broad phase ii proof-of concept programm
focuss around aml/md nsclc also cover varieti addit
oncolog indic treatment set investigator-sponsor trial
exhibit far particularli promis signal bemcentinib
monotherapi aml/md combin pembrolizumab nsclc
highlight across studi bemcentinib extrem well-
toler exampl advers event observ three phase ii nsclc trial
line would expect trial either pembrolizumab
erlotinib docetaxel respect monotherapi stage appear
bemcentinib use combin therapi toler
perspect import aspect profil high select
receptor bemcentinib greatest commerci potenti probabl use
combin variou drug
bergenbio current plan randomis phase ii studi probabl
potenti becom pivot studi assess bemcentinib activ
rigor detail disclos yet though start
diagnost programm well
invers relationship
circul activ
companion diagnost also develop
conjunct clinic trial bergenbio also companion diagnost
programm bemcentinib understand centr relat
biomark assay primarili focus immunohistochemistri assay
identifi accur express solid tumour blood test
detect solubl aml/md
test initi use investig activ bemcentinib
patient tumour cell express differ level receptor
reassuringli better respons seen patient axl
tumour discuss current clinic trial bergenbio also analys
correl patient respons express receptor
immun cell locat within tumour nk cell macrophag
data latter publish date outcom analysi
determin whether bergenbio stratifi patient solid tumour accord
express tumour cell sole express tumour immun
saxl blood test low level saxl appear indic aml/md
patient superior respons bemcentinib treatment compar
high saxl level alreadi shown set
invers relationship level activ receptor
blood exhibit extracellular domain receptor shed
follow receptor cleavag shed process known mechan
downregul membran receptor normal physiolog condit
tumour signal pathway inact rel high-
level receptor shed convers receptor bound ligand
tumour activ signal receptor stabilis
less like cleav
triniti delta exhibit receptor tyrosin kinas neg regul receptor shed
bergenbio adapt miller et al ccr
earli clinic programm
help mani way
patient treat bemcentinib increas saxl level observ
aml/md nsclc combin trial erlotinib pembrolizumab
melanoma clinic studi consist bemcentinib target activ
inhibit activ receptor increas tumour shed
potenti biomark identifi date need valid subsequ
clinic trial howev could use companion diagnost test
identifi patient like benefit treatment bemcentinib
respond therapi could increas likelihood
bemcentinib reach market enhanc drug commerci prospect
exhibit summari result company-sponsor phase ii studi
bergenbio note garon et al pembrolizumab treatment nsclc nejm adam et al phase ii
studi pembrolizumab monotherapi previous treat mtnbc cohort clin oncol
bemcentinib phase ii data far
result date company-run phase ii studi summaris exhibit
investigator-sponsor trial shown exhibit data particularli
promis two indic review indic efficaci data nsclc
aml detail find underpin bergenbio decis focu
develop bemcentinib lung cancer aml
exhibit summari result investigator-sponsor phase ii studi
bergenbio note garon et al ramicirumab plu docetxel vs placebo plu docetaxel treatment stage iv nsclc
diseas progress platinum-bas therapi revel multicentr double-blind randomis phase trial lancet
phase ii nsclc combin checkpoint inhibitor
increasingli matur data phase ii studi bemcentinib combin
pembrolizumab previous treat lung adenocarcinoma
immunotherapi nave present wclc septemb
novemb reinforc earlier find initi result present
see updat note june result show bemcentinib
enhanc pembrolizumab activ patient axl-express tumour
particularli tumour would normal respond
pembrolizumab monotherapi recent result shown exhibit
exhibit waterfal plot best respons patient phase ii nsclc trial pembrolizumab
updat data io set
continu suggest bemcentinib
enhanc activ
pembrolizumab nsclc
put data context use compar two
pembrolizumab monotherapi trial conduct merck
keynot larg phase studi variou cancer includ
nsclc all-com
keynot phase studi nsclc compar pembrolizumab
monotherapi versu docetaxel patient
exhibit subgroup analysi best respons biomark express nsclc phase ii pembrolizumab
patient group number patient
exhibit kaplan meier curv phase ii nsclc trial pembrolizumab axl /- patient
includ patient
keynot phase studi nsclc patient orr pd-
patient compar orr
bemcentinib trial far similarli median patient
weak high express tumour respect
month respect compar month
patient axl tumour includ posit tumour
bemcentinib trial howev note nsclc
patient keynot alreadi receiv least two line system
treatment line patient wherea patient current trial
second-lin set
also orr keynot phase trial similar set
tumour orr current studi
intention-to-treat popul contain patient numer
compar howev note stratifi
contain posit tumour approxim equal number
patient weak high express respect
consist high patient shown best outcom highest
respons rate surviv benefit pembrolizumab monotherapi
triniti delta respons rate axl-posit
comparison trial heavili slant toward neg patient
weak patient patient contain high
patient patient unclassifi median seven patient
express tumour bemcentinib trial also compar favour
month keynot studi reach
month current trial
respons rate patient axl-posit tumour notabl
orr patient includ four neg tumour
indic express tumour could act valuabl biomark
identifi patient like benefit bemcentinib treatment
trial still on-going pre-specifi efficaci endpoint first stage
phase ii trial least four clinic respons first treat patient
met trial advanc second stage addit
patient recruit clinic trial design os data
first stage trial expect initi orr data second
stage trial due report similar time
current trial second-lin immunotherapi nave patient popul
gradual shrink standard care non-squam nsclc rapidli
evolv patient receiv inhibitor first-lin
set inhibitor monotherapi use patient tumour
express high level inhibitor combin
chemotherapi increas use patient could lead
bergenbio expand current trial assess activ bemcentinib
combin pembrolizumab patient immunotherapi
phase ii nsclc trial combin egfr inhibitor
phase ii studi combin erlotinib design
assess potenti bemcentinib egfr mutation-driven megfr nsclc
relat potenti revers tumour resist erlotinib
exhibit waterfal plot best respons megfr nsclc erlotinib
bemcentinib appear re-
sensitis nsclc tumour
delay resist
erlotinib develop
bergenbio note specif mutat egfr protein amino acid
previous report patient respond bemcentinib
combin erlotinib second-lin set poster present wclc
confirm exhibit support hypothesi bemcentinib
re-sensitis tumour develop resist erlotinib via axl-driven bypass
mechan rather resist mutat clinic
perspect patient patient progress first-gener egfr
target therapi greatest clinic need patient
egfr mutat well-treat astrazeneca osimertinib tagrisso
therefor bemcentinib commerci potenti megfr nsclc patient
without specif mutat similar resist
resistance-prevent first-lin set arm studi enrol criteria
meant patient receiv erlotinib monotherapi least week
without diseas progress patient receiv bemcentinib addit
erlotinib alreadi take thu tumour shrinkag observ
top benefit seen patient erlotinib monotherapi prior
entri trial respons data still immatur far one
patient trial arm achiev partial respons
greater interest initi data appear confirm bemcentinib
least delay develop resist erlotinib exhibit median
pivot phase studi erlotinib first-lin megfr nsclc
month median data current trial matur alreadi
greater month includ time patient receiv erlotinib
monotherapi median time month
alway sensibl cautiou compar data two differ trial
especi instanc trial design resistance-prevent arm
current studi pivot studi erlotinib quit differ
howev data trial promis opinion would justifi
advanc develop bemcentinib set erlotinib
anoth egfr inhibitor larger phase ii studi improv understand
abil delay/prev develop resist egfr inhibitor
bergenbio note chart includ period time patient treat
erlotinib monotherapi receiv bemcentinib erlotinib combin
phase ii nsclc studi combin chemotherapi docetaxel
latest data includ data phase ii combin trial bemcentinib
docetaxel adenocarcinoma nsclc suggest clearli
two compound work synergist demonstr preclin
studi bemcentinib delay develop docetaxel resist
orr data suggest
bemcentinib delay resist
docetaxel develop
exhibit chang sum target lesion time week patient phase ii docetaxel combin studi
orr studi date two partial respons patient
treat far trial on-going compar orr normal seen
docetaxel monotherapi exhibit also median month
studi vs month docetaxel monotherapi histor trial exhibit
exhibit kaplan meier curv phase ii trial nsclc combin docetaxel
saxl level blood
appear accur identifi
aml/md patient like
respond bemcentinib
latest data publish phase ii studi
relaps refractori acut myeloid leukaemia aml myelodysplast
syndrom md continu demonstr promis level efficaci
bemcentinib monotherapi exhibit interest aspect data
concern strong correl low level solubl
invers relat level signal biomark high activ
bemcentinib aml/md patient achiev clinic respons
bemcentinib monotherapi patient class low
saxl blood
exhibit subgroup analysi best respons biomark express phase ii aml/md trial
number
bergenbio note cr complet respons complet respons incomplet haematolog recoveri crp complet
respons incomplet platelet recoveri
exhibit durat treatment saxl low patient top saxl high patient
bottom month
benefit
bemcentinib treatment
probabl due immun
also note immunolog data indic
diversif t-cell repertoir seven eleven patient assess
follow bemcentinib monotherapi also similar
diversif b-cell repertoir two patient exhibit
data suggest benefit observ bemcentinib
studi could due better anti-tumour immun surveil also lend
support combin bemcentinib treatment checkpoint inhibitor
pembrolizumab
exhibit diversif b-cell igh t-cell receptor tcr
repertoir patient receiv bemcentinib monotherapi
clinic trial on-going patient receiv bemcentinib
combin chemotherapi low dose cytarabin decitabin first
line set decitabin combin arm trial fully-recruit
result expect potenti bemcentinib monotherapi high-
risk md assess well investigator-l phase ii bergamo
studi recent initi
updat data phase ii trial metastat melanoma
present poster trial cross-ov design
bemcentinib use combin either pembrolizumab dabrafenib
novarti tafinlar plu trametinib novarti mekinist newly-
efficaci data melanoma trial
look promis soon
draw conclus
exhibit clinic trial design phase ii trial melanoma
triniti delta exhibit waterfal plot best respons patient phase ii melanoma trial
reassur
combin well toler
far data patient publish exhibit seventeen patient
achiev diseas control two complet respons although
soon draw meaning conclus efficaci variou drug
combin data said reassur drug
combin well toler far often possibl use two
drug combin advers event specif
bemcentinib mean problem drug combin
bemcentinib test date
progress bergenbio make bemcentinib combin
grow interest target signal oncolog result
follow studi planned/initi
phase ii bergamo studi patient high-risk md
aml bemcentinib monotherapi led prof uwe platzbeck
univers leipzig germani start begin januari
trial assess valu potenti predict
pharmacodynam biomark md associ patient
benefit bemcentinib
phase ii mist studi malign mesothelioma run prof
dean fennel univers leicest uk evalu bemcentinib
combin pembrolizumab three treatment regimen
first patient due enrol
phase ib/ii studi pancreat cancer assess potenti
combin bemcentinib chemotherapi expect start
princip investig muhammad beg md
univers texa southwestern medic center us trial
support stand cancer
phase ii studi glioblastoma bemcentinib use adjuv
set follow tumour resect trial led dr burt
nabor univers alabama us start end
potenti oncolog fibrosi
bergenbio initi clinic develop januari
monoclon antibodi inhibit receptor exhibit phase studi
healthi volunt compani expect start phase i/ii studi
patient compani yet disclos detail
develop plan indic plan target
exhibit characterist monoclon antibodi
could explor oncolog
indic fibrosi
immun respons
share common featur
bergenbio could develop oncolog target differ cancer
indic bemcentinib might decid develop monoclon antibodi
treat fibrosi inhibitor potenti block diseas process
fibrosi occur normal heal process goe awri format
excess scar occur tissu sever impair function
affect organ initi caus fibrosi manifold
precis diseas process fulli understood typic involv common
seri event includ secret cytokin provok pro-fibrot
chronic inflammatori immun respons lead product excess
extracellular matrix ecm protein collagen tissu becom fibrou
natur inhibit receptor block initi stage fibrot
process howev progress fibrosi vari differ tissu
role might vari nevertheless target receptor could
effect treatment fibrosi mani tissu
immun respons aggress tumour fibrot tissu similar
develop chronic inflamm exhibit convers
inhibit signal result trigger respons inhibit
also appear prevent product ecm fibroblast espindola et al
ajrccm prove bemcentinib could inhibit product ecm
migrat prolifer fibroblast ipf model importantli also
discov high express associ patient rapidli
exhibit role immun system fibrosi
market could segment
phase studi out-
licens
start januari
bergerbio could develop either bemcentinib fibrosi one way
could better suit chronic fibrosi therapi given biolog
tend associ better medic adher oral drug
chronic indic addit could greater price flexibl
develop fibrosi hybrid strategi possibl
exampl bergenbio might develop bemcentinib idiopath pulmonari fibrosi
ipf price would compar oncolog
develop common fibrot condit eg liver renal fibrosi
antibody-drug conjug
bergenbio partner anti-axl antibodi drug
conjug programm follow juli deal
bergenbio out-licens two proprietari anti-axl monoclon
antibodi develop took
respons fund develop asset phase trial
local advanc metastat solid tumour start januari
compos humanis antibodi human
link cytotoxin exhibit antibodi portion bind cell
express surfac internalis intracellular
enzym cleav linker releas cytotox payload interfer
preclin data support
two-part phase track start
enrol
bergenbio elig
develop regulatori sale
note compos humanis antibodi
human site-specif conjug use glycoconnect technolog
contain hydraspac valine-alanin cleavabl linker pyrrolobenzodiazepin
preclin studi demonstr dose-depend potent vitro
vivo anti-tumour activ variou cancer model recent preclin
data present poster april support
develop demonstr
potent highli target vitro cytotox panel axl-
potent durabl anti-tumour efficaci singl low dose breast
renal cancer-deriv xenograft show similar activ
axl-neg xenograft model
favour therapeut index excel stabil vivo half-
life day mg/kg day maximum
toler dose mg/kg pk analysi non-tumour bear rat
open label multicentr singl arm phase studi enrol
patient two-part design dose-escal part standard
dose escal design determin maximum toler dose
and/or recommend dose expans part dose-expans phase
consist three cohort one select tumour type
cohort enrol patient studi evalu safeti toler
pharmacokinet anti-tumour activ year
includ biomark test compon studi read-out anticip
agreement grant exclus global licens
bergenbio ipr develop commercialis therapeut product
companion diagnost exchang mileston sale royalti first
mileston trigger dose fifth
patient phase studi expect
total bergenbio could receiv mileston per
product split achiev develop regulatori
mileston sales-bas mileston compani also
elig two-tier mid-rang singl digit royalti global net sale
product relat companion diagnost payabl minimum
year first sale countri addit world-wide net sale
exceed aggreg first time given calendar year
therapeut requir pay one-tim low eight-figur sale mileston
use valid axl-adc
bemcentinib advanc
inhibitor develop
promis profil allow use
combin agent
approach target express cell receiv clinic
valid genmab progress humax-axl-adc dose-escal
part phase i/ii studi seven differ solid tumour
complet phase iia expans cohort initi june
detail trial design present recent capit market
day septemb clinic data releas date
promis case report stage nsclc unmut patient verbal
discuss genmab guid data expans cohort
estim first clinic trial data phase studi
publish provid indic potenti
importantli compar genmab humax-axl-
competit target
unsurprisingli bergenbio face grow competit develop therapi
receptor exhibit potenti target oncolog
beyond becom better appreci fortun still
advanc select small-molecul inhibitor clinic develop thank
astut decis in-licens bemcentinib formerli known
san francisco-bas biotech discuss
also first monoclon antibodi enter clinic
though estim two year behind
genmab humax-axl-adc develop
top bergenbio three advanc programm target also
import recognis select therapi could
particularli import bemcentinib confer signific competit
advantag appear inhibitor exclud adc greatest
commerci potenti use combin agent data
bemcentinib far indic safe combin erlotinib
pembrolizumab docetaxel without dosag reduct contrast trial
combin astellass gilteritinib erlotinib nsclc termin
treatment patient due advers event although note
mirati sitravatinib well toler combin nivolumab
bergenbio companion diagnost programm bemcentinib could also
expedit product rout market provid bergenbio signific
competit advantag moment appear greatest competit
bemcentinib like come sitravatinib solid tumour phase studi
nsclc immunotherapy-experienc patient due start
gilteritinib aml phase on-going newli diagnos aml regardless
statu neither product axl-rel companion diagnost
programm assum three product eventu compet market
oncologist abl identifi patient like respond
inhibitor prescrib bemcentinib companion diagnost could also enabl
bemcentinib reimburs favour
antibodi current appear clinic develop howev arav
develop fc-fusion protein sequest therebi prevent
signal phase i/ii ovarian cancer
exhibit oral inhibitor develop
approv medullari thyroid cancer
renal cell carcinoma ph ii
solid tumour inc nsclc
approv cml ph ii gbm breast
solid tumour
approv aml
mutat phase line aml all-
start phase ii checkpoint
inhibitor bladder cancer rcc
nsclc solid tumour
aml nhl solid tumour breast
cancer nsclc
nsclc combin
osimertinib gefitinib
exhibit adc develop
drug antibodi ratio
pbd
valine-citrullin link
disclos
phase start
init april cohort patient
phase i/ii first patient februari
triniti delta in-licens bemcentinib
inspir deal
payment term back-end
load depend term
believ licens deal
like order maximis
overal valu bemcentinib
in-licens deal rigel bemcentinib
bergenbio initi focus develop monoclon antibodi
becom awar rigel inhibitor asset opportunist in-
licens variou select inhibitor compani june back-
end weight deal subsequ bergenbio prioritis develop
small molecul bemcentinib formerli known
term rigel deal bergenbio obtain world-wide exclus
right bemcentinib eight back-up compound right sub-licens
asset exercis option in-licens nine inhibitor rigel
june exchang bergenbio agre make variou payment
rigel far paid time-bas payment
similar payment februari relat
first phase ii initi first product futur payment depend
whether product developed/commercialis in-hous partner
bergenbio continu develop commercialis bemcentinib
compani follow mileston payment oblig
initi first phase studi first product
nda submiss equival first product
mileston approv first drug
addit rigel elig tier royalti net sale
sale
bergenbio out-licens bemcentinib payment base revenu share
model need made rigel accord schedul
revenu partner prior complet phase ia
complet first phase ia studi
complet first phase ib studi
complet first phase ii trial
complet first phase ii trial patient
complet phase studi
septemb bergenbio rigel enter arbitr respect
interpret applic certain provis origin licens
agreement particularli relat right oblig event sub-
licens sale bemcentinib back-up expect arbitr
conclud end-march
bergenbio evalu partner option bemcentinib final
decis depend clinic data believ like
bergenbio look partner bemcentinib larg player complet
current programm phase ii studi assum data trial confirm
bemcentinib potenti treat broad rang tumour combin
variou regimen target therapi immuno-oncolog chemotherapi
consider resourc would requir conduct broad phase oncolog
programm would necessari maximis valu bemcentinib
phase ib/ii trial aml nsclc erlotinib expect recruit
patient therefor believ bergenbio pay revenu
receipt rigel enter sub-licens agreement
triniti delta clinic trial result key
trial requir also
make bemcentinib
everyth hing current
proof concept trial
axl role inevit attract
possibl larger
usual drug
main risk bergenbio current relat outcom clinic
trial initi result promis true potenti bemcentinib
becom appar complet data phase ii studi
broad programm combin biomark analysi partial de-risk
compani recognis bergenbio develop first-in-class
product biolog particularli complex fulli understood
also possibl bemcentinib might also greater effect overal
surviv os progress free surviv seen
bergenbio yet decid whether take bemcentinib market
partial/ful out-licens product novelti compound
make develop process challeng mean like
commerci attract prospect partner especi broad
potenti oncolog therapi assum current trial success
bergenbio look partner bemcentinib import appreci
best deal might one greatest bio-dollar one
commit partner devot suffici resourc optimis
develop bemcentinib current focus aml/md nsclc
variou set monotherapi target therapi chemotherapi
checkpoint inhibitor pembrolizumab sever investigator-l
trial could lead expans programm result
phase ii programm determin indic bergenbio target
bemcentinib decis base scientif commerci
consider potenti bemcentinib immuno-oncolog therapi
agent particularli excit howev field highli competit
although bemcentinib current advanc select inhibitor
develop probabl other enter clinic
import role play emt chemotherapi resist immuno-
oncolog better understood clearli rate bergenbio advanc
bemcentinib determin first-mov advantag reach market
top specif risk also typic risk associ
drug develop includ patent litig financ regulatori
uncertainti regard patent posit composit matter patent
due laps without extens
patent pend cover use bemcentinib
protect compound competit also
variou patent award pend could provid degre
protect
suggest valu
share
low cost product mean
attract
expect raft news flow
bergenbio classic drug develop compani well-suit
valuat use rnpv methodolog typic rnpv individu clinic
project adjust success probabl sum net
cost run oper case bergenbio valu
bemcentinib indic current develop
success probabl base standard industri criteria stage
clinic develop process flex reflect data indic
use approach valu bergenbio equival
detail valuat shown exhibit
increas previou valuat
due addit enter clinic develop
throughout valuat continu use conserv assumpt
line polici includ valuat yet
know compani develop plan asset
prudent assum averag cost treatment per patient across
indic us two third price europ
compar estim averag cost treat patient astrazeneca
osimertinib tagrisso merck pembrolizumab keytruda
believ sensibl given limit clinic data also
bemcentinib potenti use treat solid tumour either
combin chemotherapi immunotherapi low cost
good rel low price might settl upon ensur
reimburs issu hinder adopt
share current trade valuat bergenbio
expect differ reduc come year clinic data
report exhibit next six month expect result present
may june possibl confer well new
data could act share price catalyst eagerli await result
overal surviv data first stage phase ii studi nsclc
pembrolizumab result trial second stage hope
confirm find first stage data report
triniti delta exhibit rnpv-base valuat bergenbio
bemcentinib
bemcentinib
nsclc
bemcentinib
nsclc
bemcentinib
nsclc
bemcentinib
solid
base
indic
pembrolizumab
success
likelihood receipt
revenu payabl rigel
triniti delta note valuat assum out-licens lose patent protect valu
indic includ current expens associ current clinic trial hnscc head neck squamou cell carcinoma chl
start
triniti delta oper cost forecast rise
pipelin matur
runway
bergenbio gradual increas invest would expect
compani situat broad phase ii programm lead compound
bemcentinib second asset enter clinic develop
result compani oper cost increas
forecast trend continu
estim oper expens
stage know bergenbio plan random phase ii
studi bemcentinib due start develop
programm disclos revis
estim appropri also like bergenbio receiv mileston
payment trigger dose fifth patient
phase studi estim worth
conserv includ forecast
bergenbio strong balanc sheet cash posit
cash debt compani rais net
gross privat placement issu share
per share april also make use non-dilut sourc fund
possibl exampl current negoti research council
norway grant three year fund research
axl role fibrot diseas estim compani current
suffici cash oper though would consider
extend bergenbio partner bemcentinib
signific chang made estim follow
initi phase ii studi pancreat cancer chemotherapi
initi phase ii studi mesothelioma chemotherapi
initi phase ii studi glioblastoma adjuv set
os data stage one phase ii nsclc trial pembrolizumab
initi top-lin data stage two phase ii nsclc trial pembrolizumab
initi top-lin data phase ii aml/md trial chemotherapi
mileston trigger dose fifth patient phase trial
headlin data phase i/ii second-lin nsclc trial docetaxel
headlin data phase ii melanoma trial pembrolizumab braf/meki
headlin data phase ii glioblastoma trial
initi randomis phase ii studi
initi phase ib studi
exhibit summari financi
compani triniti delta note short-term debt indic compani fund requir
triniti deltayear-end dec good oper profit financ tax incom ep share marginn/an/an/an/an/abal sheetcurr cash current plant non-curr current non-curr statementsoper cash work cash tangibl invest cash cash financ cash increas rate start end cash end tel
join februari senior industri
experi execut board level
former execut dyno industri fine
chemic becam ceo pharmaceut firm
nycom subsequ merg amersham
plc thereaft merg ge head
isco group execut search corpor
advisori group co-found
norgesinvestor oslo-bas privat equiti
firm first chairman
investinor vc norwegian state
chairman algeta asa pharmaceut
start-up develop xofigo acquir
bayer previou chairman posit
public variou industri enterpris
join chief execut offic
year industri experi drug
develop commercialis previous
serv ceo aenova inc specialist
biopharmaceut compani prior
manag director dcc healthcar ltd
also held posit reckitt
benckis commerci role qualifi
pharmacist liverpool univers
receiv bath univers
join cfo year
corpor govern advisori experi
public privat compani across multipl
sector prior role includ cfo rema franchis
norg variou role increasingli
respons ey recent execut
director regist account state
join octob research director
promot cso year
drug discoveri experi small molecul
biolog therapeut manag
strateg allianc pharma lead
sever novel programm oncolog earli
research clinic studi prior role
includ senior manag director level
posit british biotech
piram pharma cancer research technolog
cellcentr hold doctor univers
oxford oxford brook univers
co-found cso professor
depart biomedicin univers
research focus cancer research prof
loren author peer-review
articl numer patent work rigel
complet postdoctor studi stanford
univers manag mani larg
collabor major pharmaceut
triniti delta research limit tdrl firm refer number trade triniti delta appoint repres
equiti develop limit ed content report prepar sole respons tdrl
review independ verifi ed authoris regul fca whose refer number
ed act tdrl person respons provid protect provid client tdrl
advis person connect content report except extent requir applic law
includ rule fca owe duti care person relianc may place ed advic
recommend respect content report extent may applic law ed make
represent warranti person read report regard inform contain
prepar report tdrl use public avail sourc taken reason effort ensur fact state
herein clear fair mislead make guarante warranti accuraci complet inform
opinion contain herein provid updat fresh inform becom avail opinion chang
person relev person section section financi servic market act unit
kingdom act reli document content research client compani produc tdrl normal
commiss paid compani issuer financ research deem independ
defin fca object author state opinion report consid market
commun purpos fca rule prepar accord legal requir design promot
independ invest research subject prohibit deal ahead dissemin invest research
tdrl hold posit compani mention report although director employe consult tdrl
may hold posit compani mention tdrl impos restrict person deal tdrl might also provid servic
compani mention solicit busi
report provid relev person provid background inform subject matter note document
constitut form part constru offer sale purchas solicit invit
make offer buy sell secur may rise fall valu shall part form basi reli
connect contract commit whatsoev inform provid intend
manner whatsoev constru personalis advic self-certif investor complet free charg
www fisma org tdrl affili offic director employe ed liabl loss damag aris use
document maximum extent law permit
inform avail websit www trinitydelta org
